Cardiff Oncology, Inc. (CRDF) vs Fortress Biotech, Inc. (FBIO)

Cardiff Oncology, Inc. and Fortress Biotech, Inc. are both Biotechnology companies. Cardiff Oncology, Inc. and Fortress Biotech, Inc. are of similar size ($61.4M and $58.8M). Cardiff Oncology, Inc. has negative trailing earnings, so its P/E is not meaningful; Fortress Biotech, Inc. trades at 0.6×. Fortress Biotech, Inc. grew revenue faster over the last twelve months: 15.5% against −6.79%. Fortress Biotech, Inc. has the higher net margin (151.0% vs −7,889.0%) and the lower return on invested capital (−41.3% vs 0.00%). Across the 18 metrics below, Fortress Biotech, Inc. leads on 14 and Cardiff Oncology, Inc. on 4.

Valuation

Metric CRDF FBIO Biotechnology median
P/E n/m 0.56 10.26
P/S 102.33 0.85 9.18
P/B 1.96 0.28 2.05
Price to free cash flow n/m 0.68 24.81
EV/EBITDA n/m 4.91 0.65
EV/Sales 37.15 (1.46) 8.98
Earnings yield (78.95%) 177.17% (34.89%)
Free cash flow yield (78.76%) 146.75% (24.52%)

Profitability

Metric CRDF FBIO Biotechnology median
Gross margin 100.00% 65.59% 65.16%
Operating margin (8,320.08%) (42.61%) 0.00%
Net margin (7,888.98%) 150.98% 0.00%
Free cash flow margin (8,059.45%) 183.80% 0.00%
Return on equity (94.14%) 84.91% (50.12%)
Return on assets (70.89%) 43.38% (45.60%)
Return on invested capital 0.00% (41.34%) 0.00%

Growth

Metric CRDF FBIO Biotechnology median
Revenue growth (TTM) (6.79%) 15.46% 6.26%
EPS growth (last fiscal year) 27.37% 97.40% 29.88%
Revenue growth, 5-year CAGR 10.13% 6.77% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CRDF FBIO Biotechnology median
Debt to equity 0.00 0.17 0.00
Current ratio 3.30 3.96 4.89
Net debt to EBITDA 1.18 0.43 1.01

Dividend

Metric CRDF FBIO Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CRDF FBIO Biotechnology median
Market cap 58.76m 61.36m 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack